Search Results 1641-1650 of 20425 for hepatitis

1. Etanercept-szzs (subcutaneous route) - Side effects & dosage - Mayo Clinic

   ... hepatitis. Check with your doctor right away if you or your child have fever or chills, a general feeling of discomfort, illness, or weakness, light-colored ...

2. Alumni - Center for Clinical and Translational Science

   D., Hepatitis B and hepatitis C as risk factors for hepatocellular carcinoma in Somali immigrants — Role of viral genetics/epigenetics and the immune ...

3. A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) - Mayo Clinic

   Active Hepatitis B or C. This only needs to be excluded in patients where there is clinical suspicion of hepatitis (e.g., elevated LFTs). 8. Female patients ...

4. Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck - Mayo Clinic

   Active infection including hepatitis B, hepatitis C or human immunodeficiency virus (HIV);; Receipt of live, attenuated vaccine within 30 days prior to the ...

5. A Study To Confirm the Effectiveness and Safety of Terlipressin in Adults with Hepatorenal Syndrome Type 1 - Mayo Clinic

   ... hepatitis, or toxins (e.g., Amanita toxin with mushroom poisoning carbon tetrachloride), with the exception of acute alcoholic hepatitis. Proteinuria ...

6. A Study To Evaluate The Efficacy And Safety Of Tulisokibart (MK-7240) In Participants With Moderate To Severe Crohn's Disease (MK-7240-008) - Mayo Clinic

   * Is infected with Hepatitis B virus (HBV), Hepatitis C virus (HCV), or human immunodeficiency virus (HIV). * Has active tuberculosis. * Has confirmed or ...

7. Ofatumumab (intravenous route, subcutaneous route) - Side effects & dosage - Mayo Clinic

   Hepatitis B, active—Should not be used in patients with this condition. Hepatitis B, history of or; Liver disease, history of—Use with caution. May make ...

8. A Phase 1/​2 Study of STP938 for Adult Subjects With Relapsed/​Refractory B-Cell and T-Cell Lymphomas - Mayo Clinic

   - Known active or chronic hepatitis B or active hepatitis C virus (HCV) infection. - Subjects who have received a live vaccine within 30 days prior to study ...

9. A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer) - Mayo Clinic

   Active hepatitis B virus (HBV) or hepatitis C (HCV) infection;; Severe infection within 4 weeks prior to initiation of study treatment;; Significant ...

10. Effectiveness and Safety of Pembrolizumab for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer - Mayo Clinic

    Has a known history of Hepatitis B or Hepatitis C. Has a known history of active tuberculosis. Has a history or current evidence of any condition, therapy ...